-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

Benzinga·12/08/2025 10:16:42
Listen to the news
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $38 to $30.